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Abstract
Background: Some antiepileptic drugs (AEDs) induce expression of hepatic enzymes. This can contribute to
comorbidities via interference with metabolic pathways and concomitant drug metabolization, thereby increasing
the likelihood of health care interventions. Using medical records, we compared the direct health care cost in
patients initiating epilepsy therapy with enzyme-inducing AEDs (EIAEDs) vs non-enzyme-active AEDs (nEAAEDs)
over up to 12 years.
Methods: Patients with untreated epilepsy were indexed in the UK Clinical Practice Research Datalink and Hospital
Episode Statistics database when prescribed a new EIAED or nEAAED between January 2001 and December 2010.
Propensity score matching reduced confounding factors between cohorts. Patients were followed until cohort treatment
failure or data cut-off. The primary outcome was the median standardized monthly direct health care cost during follow-
up in 2014 £GBP, calculated using published reference costs and compared using a Mann–Whitney U test.
Results: The unmatched EIAED cohort (n = 2752) was older (54 vs 46 years), more likely to be male, had more
comorbidities, and higher health care resource use/cost during the 1-year pre-index period (median £3014 vs
£2516) than the nEAAED cohort (n = 2,137). The most common index EIAED and nEAAED were carbamazepine
(63.3%) and lamotrigine (58.0%), respectively. After matching, cohorts had similar features (n = 951 each). Over up
to 12 years of follow-up, the median standardized monthly direct health care cost was £229 for the EIAED and
£188 for the nEAAED cohorts (p = 0.0091). The median cost was higher for the EIAED cohort in every year of
follow-up. In the two cohorts, 25.1% and 20.1% of total mean cost during follow-up was epilepsy-related, with
approximately 4.6% and 3.0% for AED acquisition, respectively. The median time to cohort treatment failure was
shorter in the matched EIAED cohort (468 vs 1194 days).
Conclusions: Patients in the UK who initiated epilepsy therapy with an EIAED appeared to be at higher risk of
complications associated with enzyme induction. In long-term matched cohort analyses, the median total direct
health care cost associated with EIAED therapy was higher than with nEAAEDs. Changing current treatment
practices could potentially improve patient outcomes and reduce costs.
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Background
In 2010, the Joint Epilepsy Council of the UK and
Ireland estimated that 0.97% of the UK population
(~602,000 people) had epilepsy [1]. For many patients,
epilepsy is a chronic disorder that requires long-term
antiepileptic drug (AED) therapy. A broad array of
AEDs is available, with varying mechanisms of action
and pharmacokinetic profiles. Enzyme-inducing AEDs
(EIAEDs), such as carbamazepine and phenytoin,
stimulate the synthesis of endogenous cytochrome
P450 (CYP450) enzymes as an off-target effect. Only a
few CYP450 enzymes are responsible for approxi-
mately 80% of all oxidative drug metabolism [2]. Con-
sequently, treatment with enzyme-inducing drugs can
potentially lead to altered metabolization of some con-
comitant drugs, and requires a distinct set of treat-
ment considerations [2–4]. Other AEDs, such as
oxcarbazepine and topiramate (mild EIAEDs), induce
only a few CYP450 enzymes, while valproate is a
CYP450 inhibitor [2, 5].
Although non-enzyme-active AEDs (nEAAEDs) such
as lamotrigine, zonisamide and levetiracetam are avail-
able [5], EIAEDs remain widely used in the treatment
of epilepsy. No clear preference for EIAED or nEAAED
prescribing is made in UK treatment guidelines, which
are developed with consideration for the balance be-
tween clinical outcomes and cost [6].
It has previously been hypothesized that EIAED
therapy could lead to higher long-term health care re-
source use and cost [2]. Firstly, patients prescribed
EIAEDs may require higher dosages of concomitant
drugs metabolized by the CYP450 system, with more
frequent primary care appointments to monitor/titrate
drug levels and manage potential side effects. Sec-
ondly, metabolic changes related to enzyme induction
may contribute to the development of comorbidities
such as osteoporosis, sexual dysfunction and vascular
disease [2, 7, 8]. Additional investigation and treat-
ment of these comorbidities may contribute to in-
creased health care costs. Thirdly, discontinuation of
EIAEDs may lead to increases in concomitant medica-
tion levels, requiring additional primary care appoint-
ments to monitor and manage any potential toxicity.
A recent literature review has shown that while
costs associated with the use of specific AEDs have
been reported, the costs associated with EIAED ther-
apy vs other AED therapy have not previously been
compared over a clinically meaningful time period [9].
Therefore, the objectives of this study were to com-
pare the characteristics of patients prescribed EIAEDs
and nEAAEDs, and to estimate and compare the all-
cause direct health care cost associated with the use
of EIAEDs vs nEAAEDs as epilepsy therapy in the
UK over up to 12 years of follow-up.
Methods
Source data
This retrospective matched cohort study used primary care
data included in the October 2014 update of Clinical Prac-
tice Research Datalink (CPRD-GOLD; The National Health
Service National Institute for Health Research & The Medi-
cines & Healthcare Products Regulatory Agency, London,
UK), linked to admitted patient care data contained in the
national Hospital Episode Statistics database (HES; Health
and Social Care Information Centre, Leeds, UK). The study
protocol was reviewed and approved by the Independent
Scientific Advisory Committee (the scientific ethics com-
mittee concerned with the use of CPRD data).
Patient selection and follow-up
The study consisted of two cohorts: patients prescribed
an index EIAED (carbamazepine, phenytoin, phenobar-
bital or primidone) and those prescribed an index
nEAAED (gabapentin, lacosamide, lamotrigine, levetirac-
etam, perampanel, pregabalin, retigabine, vigabatrin or
zonisamide). All other AEDs were not considered index
AEDs. Mild EIAEDs (eslicarbazepine acetate, oxcarbaze-
pine, rufinamide or topiramate) were not allowed during
the pre-index or follow-up periods. Given these AEDs’
mild enzyme induction profile, classifying them as either
EIAEDs or nEAAEDs, or allowing their use in follow-up,
would have potentially biased the comparison of cost
outcomes between EIAEDs and nEAAEDs. Clonazepam
and clobazam were not considered potential long-term
therapies, and their use was permitted during the pre-
index and follow-up periods.
Patients ≥ 16 years of age and diagnosed with epilepsy
were selected from the CPRD database if they were first
prescribed an EIAED or nEAAED (index AED) between
January 1, 2001 and December 31, 2010 (the selection
period). The index date was the time of first prescription
of an index AED during the selection period. Patients
could have been diagnosed on or at any time prior to
the index date. For each selected patient, CPRD and
HES data had to be available for the 1-year pre-index
period. Patients had not previously used any index AED
(i.e. any of the EIAEDs/nEAAEDs of interest) at any
time during the available data coverage and had not re-
ceived any AED treatment during the 1-year pre-index
(i.e. baseline) period. Treatment with AEDs other than
an index AED was permitted before the pre-index
period, to avoid excluding patients who had used AEDs
for non-epilepsy indications. At least 31 days of index
AED exposure were required for inclusion, in order to
include patients with short treatment durations, but at
the same time exclude patients who might not have
taken the index AED. Patients who were prescribed an
index AED but remained registered in the CPRD for less
than 31 days were nevertheless included, to avoid
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excluding patients who did take the index AED but for
whom further prescription data to determine this is un-
available. Patients starting more than one AED on the
index date were excluded.
Patients were followed until any of the following events
occurred: end of primary care or HES data coverage, end
of registration/death, cohort treatment failure (defined as
addition of an AED belonging to the other cohort or dis-
continuation of all AED(s) belonging to the index co-
hort), or addition of a mild EIAED. Patients switching
between/adding within-cohort AEDs (e.g. carbamazepine
for phenytoin) remained in follow-up.
Exposure
Exposure was defined using primary care prescription
data. We used an algorithm to impute the maximum dur-
ation of individual AED prescriptions. The most likely
maximum duration of each AED prescription was calcu-
lated as twice the median duration for all prescriptions of
that type (type defined based on generic name, dose and
package size) in the entire study database. Each day of pa-
tient follow-up was then categorised as exposed or not ex-
posed using the prescription dates and imputed maximum
durations. The end of exposure to an AED was defined as
the start date of an exposure gap longer than four times
the imputed maximum duration of the last prescription.
Baseline characteristics
Patient demographics and clinical characteristics were
identified using primary care data and read codes, and in
HES, using the International Classification of Disease
(Tenth Revision) codes. These were used to calculate a
Germaine-Smith epilepsy comorbidity index score for
each cohort [10]. Concomitant medications were identi-
fied through primary care prescription data.
Health care resource use and costs by type
The costs associated with each health care resource used
were estimated, per type, in 2014 £GBP, including any pre-
scriptions (AEDs or otherwise), primary care consultations
(general practitioner [GP] consultations and patient-
related activity at the GP practice), test procedures, acci-
dent and emergency (A&E) visits, hospitalizations and
outpatient referrals and procedures. Our costing protocol
was partly based on principles previously applied in the lit-
erature [9]. Further details on the costing procedure can
be found in the Additional file 1.
Matching
Propensity score matching was used to reduce the effect
of confounding factors between cohorts, a methodology
commonly used in studies based on observational data
[11]. EIAED and nEAAED patients were matched 1:1 on
propensity score, where propensity score was defined as
the probability of a patient being prescribed an EIAED.
The propensity scores were derived using a multivariate
logistic model. The choice of potential confounding vari-
ables used in the model was guided by the literature;
variables were selected that were likely to influence
treatment choice and affect the outcome. The estimation
process used all available patient-level characteristics at
baseline that had a minimum incidence of 1.0%, or were
significantly different between the two unmatched co-
horts when compared by either a two-sample t test, chi-
square test or Fisher’s exact test, as suitable. Table S1
shows variables that were found to be significantly differ-
ent between the cohorts prior to propensity score
matching. Patients were only included in the matched
analysis if a suitable pairing was found.
Study outcomes and statistical analyses
To compare the characteristics of patients prescribed
EIAEDs and nEAAEDs, baseline characteristics in the un-
matched cohorts were compared using unpaired, two-
sample t tests for continuous variables and chi-square
tests for categorical variables. To assess propensity score
matching success, baseline characteristics in the matched
cohorts were compared using the same procedures.
To calculate the primary endpoint, the total health
care cost per patient was summed over the follow-up
period and divided by the number of months of patient
follow-up, thus arriving at the standardized monthly dir-
ect health care cost during follow-up. Medians were
compared between the matched cohorts using a Mann–
Whitney U test. The median is preferred to the mean
because of the highly skewed distribution of the health
care cost variable. Standardized monthly cost per year
was calculated in a similar manner, by summing costs
for the year and dividing by the number of months of
patient follow-up for that year. In addition, the cost and
incidence of specific health care resources used during
follow-up for the matched cohorts were split by type;
the costs and incidence of epilepsy-related resource use
were estimated; the incidence of new non-AED medica-
tion use and (non-epilepsy) comorbid diagnoses during
follow-up were described for the matched cohorts; and
the time to cohort treatment failure and to index AED
treatment failure were compared between the matched
cohorts using Kaplan-Meier methods, censoring patients
reaching the end of follow-up. Index AED failure was
defined as the end of exposure to the AED prescribed at
index or addition of any other AED, whichever occurred
earlier. Index AED failure differs from cohort treatment
failure in that it does not allow within-cohort AED
switching or add-on.
Analyses were performed using SAS 9.3 (SAS Institute,
Cary, NC, USA). No formal power calculations for sam-
ple size were performed.
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Results
Baseline characteristics in the 1-year pre-index period
In the overall population, 4889 unmatched patients were
indexed. Patients in the EIAED cohort (n = 2752) were
older, more likely to be male and had a higher mean base-
line Germaine-Smith epilepsy comorbidity index score
than those in the nEAAED cohort (n = 2137; p < 0.0001;
Table 1). More patients with index EIAEDs had pre-index
diagnoses of cardiovascular disease (EIAED 26.1% vs
nEAAED 17.5%), hypertension (15.1% vs 11.3%) and
neoplasms (11.4% vs 6.0%). A lower proportion of patients
in the EIAED cohort received hormonal contraceptives
(3.5% vs 11.9% in the nEAAED cohort) and antidepres-
sant/antipsychotic drugs (27.4% vs 33.7%) in the 1-year
pre-index period. The largest proportion of patients
entered the EIAED cohort in 2004 (14.6%; Table 2), de-
creasing in subsequent years. Conversely, nEAAED cohort
entry steadily increased over the selection period, peaking
in 2010 (17.8%; Table 2). Carbamazepine was the most
commonly prescribed index EIAED (63.3%), and lamotri-
gine the most common index nEAAED (58.0%) (Table 2).
During the 1-year pre-index period, patients in the un-
matched EIAED cohort had a higher all-cause direct
health care cost and a higher mean epilepsy-related
health care cost than those in the unmatched nEAAED
cohort (Table 3). Patients in the EIAED cohort had
higher utilization of acute health care resources during
the 1-year pre-index period; a reflection of higher mean
numbers of A&E visits and inpatient hospitalizations per
patient (Table 3). However, the mean numbers of GP
consultations and outpatient hospitalizations were
higher in the nEAAED cohort (Table 3).
After matching, each cohort consisted of 951 patients
and baseline characteristics were similar for all available
potential confounders (Tables 1–3).
Time to cohort treatment failure and index AED failure
In the matched populations, the proportion of patients
remaining in follow-up after 1 year was smaller for the
EIAED cohort than the nEAAED cohort (49.1% vs
60.6%). The median time to cohort treatment failure
(allowing within-group AED switching) was 468 days in
Table 1 Baseline demographics and epilepsy characteristics in the 1-year pre-index period










Age, mean (SD), years 54.2 (19.8) 45.9 (19.9) <0.0001 47.7 (19.9) 48.0 (20.0) 0.7969
Age group, n (%) <0.0001 1.0000
16–20 116 (4.2) 239 (11.2) 75 (7.9) 75 (7.9)
21–30 261 (9.5) 349 (16.3) 144 (15.1) 144 (15.1)
31–40 404 (14.7) 344 (16.1) 167 (17.6) 167 (17.6)
41–50 434 (15.8) 380 (17.8) 160 (16.8) 160 (16.8)
51–60 406 (14.8) 285 (13.3) 133 (14.0) 133 (14.0)
61–70 425 (15.4) 236 (11.0) 119 (12.5) 119 (12.5)
71–80 434 (15.8) 191 (8.9) 94 (9.9) 94 (9.9)
81–90 237 (8.6) 96 (4.5) 47 (4.9) 47 (4.9)
Over 90 35 (1.3) 17 (0.8) 12 (1.3) 12 (1.3)
Gender, n (%) <0.0001 0.7130
Female 1243 (45.2) 1339 (62.7) 506 (53.2) 514 (54.0)
Male 1509 (54.8) 798 (37.3) 445 (46.8) 437 (46.0)
Germaine-Smith epilepsy-specific
comorbidity index, mean score (SD)
1.0 (2.0) 0.6 (1.6) <0.0001 0.7 (1.6) 0.7 (1.5) 0.8272
Time since first epilepsy diagnosis, years
Mean (SD) 4.5 (10.3) 8.5 (13.5) <0.0001 5.8 (11.1) 6.2 (12.0) 0.4604
Median (P25–P75) 0.2 (0.1–2.5) 1.3 (0.1–10.9) 0.4 (0.1–5.8) 0.6 (0.1–6.3)
Epilepsy type, n (%) 0.0011 0.7202
Generalized 301 (10.9) 212 (9.9) 78 (8.2) 85 (8.9)
Partial 470 (17.1) 291 (13.6) 148 (15.6) 138 (14.5)
Unspecified 1981 (72.0) 1634 (76.5) 725 (76.2) 728 (76.6)
Abbreviations: EIAED enzyme-inducing antiepileptic drug, nEAAED non-enzyme–active antiepileptic drug, P25–P75 25th to 75th percentile, SD standard deviation
at test for continuous variables, chi-square test for categorical variables
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the EIAED cohort compared with 1194 days in the
nEAAED cohort, with a total follow-up time of 2297 vs
2881 years, respectively (Fig. 1). Index AED failure
(discontinuation of index AED, switch or addition of an-
other) occurred in 68.3% of patients in the matched
EIAED cohort and 62.7% of patients in the matched
nEAAED cohort, with a median time to index AED fail-
ure of 452 days vs 869 days, respectively. Index AED
failure owing to discontinuation of the index AED oc-
curred in 41.3% of the EIAED cohort and 43.7% of the
nEAAED cohort. Most discontinuations occurred during
the first 3 months of treatment in both cohorts. Treat-
ment failure owing to an addition of another AED oc-
curred in 27.0% of the EIAED cohort and 18.9% of the
nEAAED cohort.
All-cause direct health care cost
The median (range) standardized monthly direct health
care cost over the entire follow-up period was £229
(£18–£18,613) for the EIAED cohort and £188 (£16–
£33,880) for the nEAAED cohort (p = 0.0091; Table 4).
Higher median monthly health care cost was observed
in the EIAED cohort in every year post-index, for all pa-
tients who started the year in question (Fig. 2). The dif-
ference between the cohorts became consistently greater
from year 3. When considering yearly cost for patients
completing each year of follow-up, the median yearly dir-
ect health care cost was higher in the EIAED cohort
than the nEAAED cohort in every year except year 2
(£53 difference). Similar findings were also observed
when cost was calculated only for patients who still had
an active match pairing at the start of the year.
Specific health care resource use and cost
Patients in the matched EIAED cohort had more GP
practice consultations (mean standardized per month
[standard deviation], 5.39 [5.87] vs 4.71 [4.62]) and out-
patient referrals (0.12 [0.29] vs 0.07 [0.16]), than those in
Table 2 Index year and AED










Year of index, n (%) <0.0001 0.0669
2001 298 (10.8) 70 (3.3) 45 (4.7) 55 (5.8)
2002 326 (11.8) 88 (4.1) 53 (5.6) 63 (6.6)
2003 312 (11.3) 121 (5.7) 86 (9.0) 72 (7.6)
2004 402 (14.6) 147 (6.9) 109 (11.5) 85 (8.9)
2005 314 (11.4) 190 (8.9) 106 (11.1) 96 (10.1)
2006 275 (10.0) 222 (10.4) 121 (12.7) 109 (11.5)
2007 256 (9.3) 255 (11.9) 121 (12.7) 119 (12.5)
2008 225 (8.2) 293 (13.7) 106 (11.1) 123 (12.9)
2009 206 (7.5) 371 (17.4) 130 (13.7) 119 (12.5)
2010 138 (5.0) 380 (17.8) 74 (7.8) 110 (11.6)
Index AED, n (%) <0.0001 <0.0001
EIAED cohort
Carbamazepine 1742 (63.3) — 690 (72.6) —
Phenytoin 971 (35.3) — 245 (25.8) —
Phenobarbital 26 (0.9) — 9 (0.9) —
Primidone 13 (0.5) — 7 (0.7) —
nEAAED cohort
Lamotrigine — 1239 (58.0) — 632 (66.5)
Gabapentin — 448 (21.0) — 149 (15.7)
Levetiracetam — 261 (12.2) — 126 (13.2)
Pregabalin — 185 (8.7) — 41 (4.3)
Zonisamide — 2 (0.1) — 2 (0.2)
Vigabatrin — 2 (0.1) — 1 (0.1)
Abbreviations: AED antiepileptic drug, EIAED enzyme-inducing antiepileptic drug, nEAAED non-enzyme–active antiepileptic drug
aChi-square test
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the matched nEAAED cohort. Health care cost stan-
dardized by month were higher in the EIAED cohort for
every resource category (costs of drugs [AEDs and other
medications], GP consultations, test procedures, A&E
visits, inpatient hospitalizations and outpatient referrals
and procedures) (Table 4). The median standardized
monthly cost of AED medication was £9 and £8 in the
EIAED and nEAAED cohorts, respectively. The mean
cost made up 4.6% and 3.0% of the total mean direct
health care cost.
Epilepsy-related direct health care cost
The median standardized monthly direct epilepsy-
related cost (range) was £27 (£3–£15781) for the
matched EIAED cohort and £21 (£2–£3942) for the
matched nEAAED cohort. Over the entire follow-up
period, a larger percentage of the mean direct health
care cost was epilepsy-related in the EIAED cohort than
the nEAAED cohort (25.1% vs 20.1%; Table 4). The
mean number of epilepsy-related visits per month over
the follow-up period was numerically higher in the
EIAED cohort in all categories except GP consultations.
Over the entire follow-up period, the proportions of pa-
tients requiring epilepsy-related A&E visits, GP consulta-
tions and inpatient hospitalization were slightly higher
in the nEAAED cohort compared with the EIAED co-
hort; however, these latter rates are not adjusted for dif-
fering follow-up time.
Incident comorbidities and concomitant medications
During the follow-up period, incident (new) comorbidities
diagnosed in ≥ 5.0% of the patients in either cohort in-
cluded soft tissue disorders, essential hypertension, respira-
tory infections, back pain, hypertension, joint disorders,
urinary system disorders, convulsions, falls, disorders of
skin and subcutaneous tissue, otitis externa, depression, ab-
dominal and pelvic pain and conjunctivitis (Table S2).
Incidence rates were estimated using the number of
patients with at least one new diagnosis during the post-
Table 3 Health care costs and resource use in the 1-year pre-index period










All-cause direct health care costs
in the 1-year pre-index period, £
Mean (SD) 5618 (7387) 4613 (6007) <0.0001 4540 (6765) 4416 (5944) 0.6724
Median (P10–P90) 3014 (495–14,070) 2516 (568–11,657) 2333 (452–10,863) 2283 (448–11,180)
Epilepsy-related direct health care
costs in the 1-year pre-index period, £
Mean (SD) 997 (2361) 633 (1965) <0.0001 804 (2134) 726 (2201) 0.4314
Median (P10–P90) 42 (0–2797) 11 (0–2188) 23 (0–2599) 11 (0–2599)
Health care resource use per patient
in the 1-year pre-index period
Mean (SD) number of:
GP practice consultations 35.13 (29.55) 43.69 (36.33) <0.0001 36.48 (31.92) 37.04 (31.15) 0.6973
A&E visits 0.83 (1.26) 0.70 (1.28) 0.0003 0.72 (1.41) 0.70 (1.15) 0.6173
Outpatient non-A&E referrals 0.96 (1.45) 1.27 (1.40) <0.0001 1.08 (1.35) 1.08 (1.29) 0.9446
Inpatient hospitalizations 1.64 (5.63) 1.20 (2.70) 0.0004 1.44 (7.27) 1.22 (3.41) 0.4126
Hospitalization duration, mean
(SD), days
6.96 (19.70) 3.64(11.89) <0.0001 4.30 (11.32) 4.09 (11.48) 0.6873
Abbreviations: A&E accident and emergency, EIAED enzyme-inducing antiepileptic drug, GP general practitioner, nEAAED non-enzyme–active antiepileptic drug,
P10–P90 10th to 90th percentile, SD standard deviation. at test
































Time from index date (days)
EIAED cohort (N = 951)
nEAAED cohort (N = 951)
Fig. 1 Time to cohort treatment failure in the matched cohorts.
EIAED enzyme-inducing antiepileptic drug, nEAAED non-enzyme–
active antiepileptic drug
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index period (and no diagnosis for the respective comor-
bidity during the pre-index period) divided by the total
cohort follow-up time in years (Table S2). Rate ratios
were calculated for the two cohorts. Differences between
the cohorts were observed in both directions (higher
and lower), and no relationship to exposure was ob-
served. However, many of the common (≥5.0%) incident
comorbidities were reported more frequently in the
EIAED cohort than in the nEAAED cohort, including
convulsions (1.43 times as frequently), otitis externa
(1.61 times), essential hypertension (1.31 times), nonspe-
cified fall (1.21 times), upper respiratory infections (1.20
times), other skin disorders (1.19 times) and abdominal
and pelvic pain (1.05 times). Others were slightly more
frequent in the nEAAED cohort: dorsalgia, joint disor-
ders and injuries of unspecified body region (1.07, 1.11
and 1.22 times, respectively).
Among the less common (< 5.0%) incident comorbidi-
ties, the following were reported at a markedly higher
frequency in the EIAED cohort: fracture of foot, forearm
and lumbar spine (7.33, 4.64 and 4.40 times as fre-
quently), other metabolic disorders and manic episode
(4.33 and 4.33 times as frequently). Some other comor-
bidities were more frequently reported in the nEAAED
cohort: complications and ill-defined descriptions of
heart disease, and ulcerative colitis (9.75 and 4.25 times
as often, respectively).
Table 4 Standardized monthly direct health care cost over the follow-up period
Costs are in 2014 £GBP EIAED (n = 951) nEAAED (n = 951)
Total direct all-cause health
care costs
Median (range) 229 (18–18,613) 188* (16–33,880)
Mean (SD) 495 (1016) 432 (1272)
A&E visits Median (range) 0 (0–1740) 0 (0–316)
Mean (SD) 9 (64) 6 (22)
AED medications Median (range) 9 (2–1407) 8 (2–438)
Mean (SD) 23 (58) 13 (22)
GP practice consultations Median (range) 114 (12–2816) 102 (8–1591)
Mean (SD) 161 (187) 143 (146)
Inpatient hospitalizations Median (range) 0 (0–13,337) 0 (0–33,394)
Mean (SD) 236 (830) 217 (1203)
Non-AED medications Median (range) 7 (0–797) 6 (0–939)
Mean (SD) 30 (69) 28 (71)
Outpatient, non-A&E referrals Median (range) 1 (0–489) 2 (0–284)
Mean (SD) 16 (43) 9 (22)
Test procedures Median (range) 7 (0–761) 7 (0–518)
Mean (SD) 20 (43) 16 (32)
Total epilepsy-related direct
health care costs
Median (range) 27 (3–15,781) 21 (2–3942)
Mean (SD) 124 (608) 87 (287)
Abbreviations: A&E accident and emergency, AED antiepileptic drug, EIAED enzyme-inducing antiepileptic drug, GP general practitioner, nEAAED non-enzyme–active
antiepileptic drug, SD standard deviation
*p = 0.0091 vs EIAED, calculated by Mann–Whitney U test
Fig. 2 Standardized monthly all-cause direct health care cost in each
post-index year for the matched cohorts. Whiskers extend from the
10th to the 90th percentile; boxes extend from the 25th to the 75th
percentile; center line is the median; red cross is the mean. EIAED
enzyme-inducing antiepileptic drug, nEAAED non-enzyme–active
antiepileptic drug
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The profiles of new medications prescribed during
post-index period (and not prescribed during the pre-
index period) were generally similar in the matched co-
horts. The most frequently prescribed drug classes
(other than AEDs) were antibacterial drugs (39.0% in the
EIAED cohort vs 43.8% in the n-EAAED cohort), anal-
gesics (23.0% vs 31.0%), antisecretory drugs (16.5% vs
19.2%) and topical corticosteroids (22.5% vs 23.5%).
Among all drug classes, thyroid and anti-thyroid
drugs, mucolytics, anti-diabetics and local anaes-
thetics/anti-pruritics had new prescription rates 3.73-,
2.26-, 2.14- and 2.13-fold more in the EIAED cohort
than nEAAED cohort, respectively. Topical circulatory
preparations, antiperspirants and preparations for
warts/calluses had a new prescription rate 6.00-, 5.25-
and 4.00-fold more in the nEAAED cohort than in
the nEAAED cohort, respectively.
Discussion
This study evaluated up to 12 years of retrospective
medical records from patients initiating AED therapy in
the UK. Our unmatched data showed that during the
study period (2001–2011), patients prescribed EIAEDs
as initial AED therapy were older, more likely to be male
and had more comorbidities than those prescribed
nEAAEDs. These differences were, in turn, reflected in
higher health care resource use and cost, comorbidity
and concomitant medication use in the unmatched
EIAED cohort for the pre-index year. The older age and
lower proportion of female patients initiating therapy on
an EIAED may be justified by the risks of reproductive
hormone abnormalities and interactions with hormonal
contraceptives associated with EIAED use [2, 12]. How-
ever, our findings remain somewhat surprising, as pa-
tients with pre-existing comorbidities and concomitant
medications are generally less suited to receiving
EIAEDs, owing to their potential for drug-drug interac-
tions. This would suggest that EIAED prescribing was
not optimally targeted during the assessed period.
Our findings suggest that after controlling for baseline
differences between the cohorts by propensity score
matching, the median total direct health care cost (stan-
dardized per month) associated with the use of EIAEDs
was higher than with nEAAEDs. This study was the first
to assess the relative direct cost of EIAED vs nEAAED
therapy over a clinically relevant period of time. Our re-
sults suggest that the higher cost observed for the EIAED
cohort was related to higher health care utilization in gen-
eral. We were unable to identify any specific comorbidities
linked to the higher observed costs, which might partly be
due to limitations of the coded source data. The EIAED
cohort showed higher AED costs, which might have been
unexpected, as the acquisition cost of the newer
nEAAEDs is usually higher. The larger AED costs could
be related to the more frequent need for polytherapy ob-
served in the EIAED cohort, demonstrated by the higher
proportion of patients who added another AED and the
shorter time on index AED monotherapy. Analyses of
matched patient cohorts showed a shorter time to cohort
treatment failure, and to index AED failure, for the EIAED
cohort vs the nEAAED cohort. Although these findings
might suggest poorer long-term clinical outcomes associ-
ated with EIAED therapy, the CPRD contains limited seiz-
ure frequency data, so we are unable to investigate these
suggestions. Unfortunately, the reasons for AED failure
are not readily available in the data source.
Cost analyses using CPRD data are uncommon. The
major advantage of CPRD data over other patient record
databases (such as US insurance claims databases) is that
it offers a unique source of long-term, continuous pa-
tient data. The last estimate for the direct costs of epi-
lepsy in the UK was published 22 years ago. Cockerell et
al. [13] evaluated an average of 6.6 years of health care
utilization data from up to 1195 UK patients, collected
as part of the National General Practice Study of Epi-
lepsy [14]. The cost of epilepsy to a newly diagnosed in-
dividual with epilepsy was estimated to be £611 in the
first year, decreasing to £221 in year 2 and to £169 by
year 8. Declining costs after the first year were also ob-
served in other costing studies [15, 16]. These decreasing
costs over time are dissimilar with our findings. A large
part of the observed difference is likely to be due to
methodology and study period, and results can therefore
only be reliably compared within studies. The methodo-
logical challenges of costing epilepsy is discussed in de-
tail by Cockerell et al. [13].
The profile of index AED prescription rates reflected
the evolving treatment guidelines, AED availability and
physician preferences over the 10-year selection period;
nEAAEDs were increasingly preferred as the selection
period progressed. In the UK, the National Institute for
Health and Care Excellence (NICE) assesses the value of
treatment options based on analyses of outcomes and
costs, publishing treatment recommendation guidelines
to actively influence the selection of interventions. The
guidelines recommend that patients with epilepsy initi-
ate AED treatment as monotherapy; however, a prefer-
ence for EIAED or nEAAED has not been explicitly
made. Later generation AEDs (mostly nEAAEDs) tend
to gain market approval initially as adjunctive therapy,
with a monotherapy indication added later. This leads to
a lag in treatment availability for newly diagnosed pa-
tients [17]. The peak year for patient indexing in the
EIAED cohort was 2004, which is consistent with the
2004 NICE guidelines supporting carbamazepine as a
first-line epilepsy treatment (along with phenytoin, val-
proic acid and divalproex) [18]. For the nEAAED cohort,
the peak year for patient indexing was 2010, which may
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be indicative of the changing prescribing attitudes follow-
ing the publication of the 2007 SANAD study, which
showed lamotrigine to be more clinically and cost-
effective than carbamazepine [19]. Evidence from SANAD
contributed to the 2012 update of the NICE guidelines [6],
which recommend lamotrigine, alongside four other AEDs
with differing enzyme induction properties (carbamaze-
pine, levetiracetam, oxcarbazepine and sodium valproate),
as a first-line treatment for patients with focal epilepsy.
Mild enzyme inducing AEDs were not included in either
cohort or allowed during follow-up. Given these AEDs’
mild enzyme induction profile, classifying them as either
EIAEDs or nEAAEDs, or allowing their use in follow-up,
would have potentially biased conclusions regarding cost
outcomes between EIAEDs and nEAAEDs. Based on our
data it is therefore not possible to make inferences regard-
ing the cost outcomes associated with mild enzyme in-
ducers and how they compare with those of EIAEDs or
nEAAEDs.
The nature of incident comorbidity diagnoses during
the follow-up period was generally similar between
matched cohorts. Differences between the cohorts were
observed in both directions (higher and lower). New
prescriptions for several types of drugs were less com-
mon in the EIAED cohort during the follow-up, and this
may be indicative of the increased risk of drug interac-
tions, leading to caution when selecting concomitant
drug therapies. This is also potentially reflected in the
shorter time to end of follow-up in the EIAED cohort,
as patients may require relevant treatments that are not
well suited for concomitant therapy with EIAEDs. Over-
all, findings relating to the incidence of new comorbidi-
ties or prescriptions were not clearly related to AED
exposure or type. This may have been due to the limita-
tions of using coded data.
A particular strength of our study was the patient
matching by propensity score, which utilized several
hundred available demographic and clinical characteris-
tics. By eliminating known and observable confounding
factors, patient matching allowed an accurate estimation
of the cost and time to treatment failure associated with
EIAED vs nEAAED therapy to be made in a generally
representative population of previously untreated epi-
lepsy patients. However, not all potential confounding
factors could be controlled for in this analysis. For ex-
ample, regional differences in the standard of epilepsy
care have been noted in the UK [20, 21], and may relate
to personal preferences of the GP, practice type, size, lo-
cation and local formulary access to certain AEDs. There
is also a known correlation between social deprivation
and increased epilepsy prevalence [22]. Additional rele-
vant factors may have been excluded from the propen-
sity scoring owing to lack of information in CPRD data
(e.g. seizure type and frequency). As such, there is the
chance that the results are biased by residual, unmeas-
ured confounding.
To obtain the most accurate costings, we attempted to
match each health care resource used with the most up-
to-date cost information in 2014 GBP. This approach
was taken because of the long follow-up period in our
study, and allowed comparison between the cohorts of
patients entering the study longitudinally. Costs for each
health care resource used were calculated from pub-
lished unit costs and are as accurate as possible given
the data available. The study’s primary variable summed
the value of every health care resource used over the en-
tire follow-up period. When considering cost analyses
over time, we chose to look at the standardized monthly
cost per year for all patients starting the year in ques-
tion. This had the benefit that cost data from patients
who left follow-up during the year (following treatment
success or failure) were reflected accurately in the ana-
lysis. Sensitivity analyses showed that the cost trends
and cohort comparisons were similar when cost was
only analysed for patients completing the year, and when
considering only those patients with an active match at
the start of the year. Cost analyses are nearly always esti-
mates with inherent inaccuracies, and all electronic
medical record and billing data are subject to some level
of miscoding. The AED exposure in this study was based
on sometimes incomplete prescription duration data.
Initial assessments found structured duration informa-
tion to be missing in over a quarter of individual AED
prescriptions. Therefore, a novel algorithm was used to
determine duration for each prescription, as described in
the methods. The most likely maximum duration of each
AED prescription was calculated as twice the median
duration for all prescriptions of that type (type defined
based on generic name, dose and package size) in the
entire study database. Twice the median was chosen as
the likely maximum duration in order to avoid under-
estimating a patient’s exposure to an AED; since discon-
tinuing an AED usually requires a slow down-titration, a
longer treatment duration is typically associated with the
last prescription. The end of exposure to an AED was
defined as the start date of an exposure gap longer than
four times the imputed maximum duration of the last
prescription. This ‘allowed gap’ may appear liberal but
was chosen to avoid ending exposure too soon in case of
missing data – the assumption being that in case of a
‘long’ gap followed by a ‘new’ prescription of the same
AED, it is clinically unlikely that there really was a gap.
These miscoding issues and imputation assumptions are
not expected to differ between cohorts and therefore do
not lead to bias.
Our analyses are retrospective and descriptive in na-
ture, and findings cannot be directly extrapolated to
current clinical practice, as prescription behaviour may
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have changed according to guidelines. There were sev-
eral other limitations in our study regarding information
availability, such as the lack of seizure data, reasons for
treatment discontinuation and adverse event reporting.
While our results indicate increased health care resource
use associated with the use of EIAEDs in epilepsy, the
direct cause of this use, beyond its relation to epilepsy or
otherwise, needs further investigation and will suffer
from the lack of information noted above. Epilepsy com-
prises a diverse group of disorders and our analysis was
conducted on a potentially diverse pool of patients;
therefore, it might not accurately reflect patients with
distinct subtypes of epilepsy (i.e. syndrome, localization
or aetiology), which was found to be poorly coded in
CPRD data. Furthermore, events occurring before the 1-
year pre-index period were not included in the analysis.
Taken together, there is a possibility that specific patient
subgroups are erroneously included or omitted; for
example, inclusion of those prescribed AEDs for indica-
tions other than epilepsy, and inclusion of patients mis-
diagnosed with epilepsy.
Conclusions
Our analysis of UK CPRD data suggests that during the
studied period, EIAEDs were prescribed as an initial epi-
lepsy therapy to older patients, who were more likely to
be male and had higher baseline health care resource use
and cost than patients prescribed nEAAEDs. Given the
risks associated with enzyme induction, this prescribing
pattern appears to be suboptimal. In long-term, matched
cohort analyses, a higher average total direct health care
cost and a shorter time to treatment failure were associ-
ated with EIAED vs nEAAED therapy. We conclude that
changing current treatment practices could potentially im-
prove patient outcomes and reduce health care costs.
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